Four thousand eight hundred papers on cold plasma. Zero of them have "athlete" in the title. One mentions the skin microbiome. Four are about women's health. This is not a finished science — it's a frontier with most of the map still blank, and blank is the interesting part.
Most guidance for people talking about emerging science is a list of things not to say. That's the wrong shape for a field this young. Cold plasma is producing roughly two papers a day and has been tested in humans thirty-seven times in sixteen years. The unproven space isn't a liability here. It's most of the territory.
And the honest truth is that the gaps are more interesting than the findings. "Twelve trials found improved wound healing" is a good fact. "Six hundred and sixty-two papers on plasma-activated water and nobody has ever studied drinking it" is a better one — because it's surprising, it's completely true, and it leaves the listener somewhere to go.
That's the whole thing. Wondering out loud is not a claim — it's the opposite of one. "Nobody has studied this and I think someone should" is unassailable, because you've said plainly that you don't know. You can build an entire body of work in that space and never once be wrong.
What changes the situation is selling the unproven thing, or telling a specific person it will help their specific problem. That's the moment speculation becomes a promise, and promises come with obligations. Everything short of that is open ground.
Each of these is a genuine hole in the published literature, counted this month. For each one: what's actually known, and three things you could do with it today — none of which require you to claim anything.
"There are almost five thousand papers on this and not one is about athletes. That seems mad to me."
Keep an honest log through a training block. Not evidence — but it's yours, it's real, and nobody else has one.
This is the single emptiest space on the map and the easiest to make a case for. A sports science department could run it.
"We know it kills the bad bugs. Almost nobody has checked what it does to the good ones. That's a real open question."
Microbiome swab kits are cheap and commercially available. Before and after is a genuinely interesting piece of content.
This is the question a dermatology researcher would actually want to answer. It's fundable and it's overdue.
"The first ever human trial on plasma water was about women's health. Four years later there are four papers. Four."
Ask your audience what they'd want studied. The answers are content, and they're a genuine signal.
Under-researched women's health is a funding priority almost everywhere right now. This has a live case.
"Nobody has studied drinking it. The entire literature is fifty-four quail. I find that genuinely wild."
"Why has nobody done this?" is a strong, honest video — and it's a question, not a claim.
The missing piece is basic toxicology, not a benefit trial. Cheap, fast, and it would settle an argument thousands of people are having.
"Nearly all the research is on hospital machines. Almost nobody has studied the devices people actually own."
Real-world use patterns — how often, how long, what for — are data nobody currently has.
A user community that can describe its own habits accurately is a research asset. That's not a metaphor.
"Two studies, one team, no independent replication. That's how a field opens, not how it settles."
Long-horizon, visual, easy to photograph honestly. Good content precisely because it's slow.
A second group repeating the 2025 result would change this card completely. Nobody has tried.
"Six hundred papers and nobody has ever written the summary. That's how new this actually is."
Being early to a field that hasn't organised itself yet is a real position. Say that out loud.
A review needs no lab and no funding — just a researcher with time. This is the most askable ask on the page.
"Nobody can tell you how long it lasts. That's not a scandal — it's just a young field with homework left."
Same batch, tested over days with cheap strips. Genuinely watchable, and it teaches the concept.
This is the blocker on every plasma-water product idea anyone has. Solve it and a category opens.
"Two trials, both in dogs, both positive. And then almost nothing. Vets are usually way ahead of this."
Talk to a vet. Their reaction to the two existing studies is content on its own.
Veterinary schools run trials on a fraction of a human budget. Realistically the fastest new evidence on this page.
A real question, asked on a real call, the moment someone heard that the first human trial of plasma-activated water was about women's health. It's exactly the right instinct — and it's worth walking all the way through, because the answer isn't yes or no. It's which part.
Describing what the 2022 study did, who it was in, and what they measured. Naming it as the first human trial of plasma-activated water ever published.
Completely free · do it todayFour papers in four years. Pointing at that and saying it should bother people. This is criticism of a research field, which anyone is entitled to make.
Completely free · and it's true"I'd love to see this properly studied and turned into something women could actually buy." A wish, stated as a wish. The Hopeful voice doing exactly its job.
Completely free · say it out loudAsking your audience whether they'd want it. Writing to the authors of the 2022 trial. Making the case publicly that someone should fund the follow-up. This is the most powerful thing on the list and almost nobody does it.
Completely free · and genuinely rareHere's where it changes — not because anyone disapproves, but because the obligations are real. Selling it for that purpose makes it a regulated product in both the US and UK. It rests on one trial. And nobody has solved shelf-life, so you'd be selling something whose active chemistry decays on an unknown clock.
Doable · but it's a company, not a postFour of those five steps are free, immediate, and nobody in this space is doing them. Only the fifth needs lawyers and lab work — and it's still allowed, it just isn't a weekend project.
So the answer to "could I build a business from that" is: you can build the audience for it right now, for nothing, and decide about the product later — from a much stronger position, with people already asking for it. That's a better route to the same place.
Some of what draws people to this is not science and isn't trying to be. The field imagery, the Tesla lineage, the sense that something old is being rediscovered. That material is welcome here — it just needs one thing.
A single clause is all it takes. "This isn't science, it's the part I love." Once that's said, you can talk about whatever you want, at whatever length, and nobody can accuse you of anything — because you told them exactly what they were getting.
That sentence is completely safe and it's more compelling than any claim, because it's obviously honest. Audiences forgive speculation instantly. What they don't forgive is being sold speculation dressed as fact.
The only rule in the lore lane: never let it lean on the research. Keep the labelled speculation and the cited findings in separate sentences. Blend them and the credibility flows the wrong way — the lore doesn't get more believable, the evidence gets less.
This is the part worth taking seriously, because it's real and it's available.
Researchers pick questions partly on whether anyone is asking them. A field with thirty-seven human trials and two new papers a day is one where an organised group of users is genuinely interesting to an academic — you have exactly what a wound-healing lab, a dermatology department or a veterinary school doesn't: numbers of real people, using a real device, over real time, who could be surveyed properly.
There are named research groups working on this in Florida, Virginia, Washington DC, North Carolina and Pennsylvania. They are contactable. They publish their email addresses on their papers. And the honest version of an approach — "we mapped your field, we found these gaps, and we have a community who'd take part" — is a conversation most researchers would take.
You're not an affiliate waiting for permission to describe someone else's findings. You're early in a field that hasn't been written yet, holding the one thing researchers can't easily get.
The gaps on this page aren't the parts you have to tiptoe around. They're the parts with your name still available on them.
1,648 of the 4,846 cold plasma papers are open access — free, legally, in full, no login. Below is the shortlist: every free human trial, every free review, and the best entry point into each area. One click each, straight to the full text.
You do not need a degree to read these. Read the abstract, then the discussion, then skip to the limitations — that last section is where researchers say plainly what they couldn't prove, and it's usually the most interesting part of the paper.
Go to europepmc.org, search "cold atmospheric plasma", and tick Open Access in the filters. That's the same database this whole project was built from, and it's free to everybody.
If a paper you want is paywalled, email the author and ask. Their address is on the first page, they own the work, and sending you a copy is normal academic courtesy. Most say yes within a few days.
Cold Plasma Research Library. An independent survey of the published literature on cold atmospheric plasma, compiled from Europe PMC and ClinicalTrials.gov in September 2026. Every figure is sourced and checkable.
These pages describe published research on a technology. They do not describe or endorse any product, they are not medical advice, and nothing in them should be used to make a decision about treating a health condition. Speak to a qualified clinician about anything that matters.